CoChat
Sign Up
Cited by 26

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

State of the science: Contemporary front-line treatment of advanced ovarian cancer

Hinchcliff, Emily, Westin, Shannon N., Herzog, Thomas J.·2022·Gynecologic Oncology
DOI 10.1016/j.ygyno.2022.04.021
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2022.04.021

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 28

  1. McGuire, 1996, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med., 334, 1, 10.1056/NEJM199601043340101 · DOI
  2. Kehoe, 2015, Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial, Lancet, 386, 249, 10.1016/S0140-6736(14)62223-6 · DOI
  3. Vergote, 2010, Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N. Engl. J. Med., 363, 943, 10.1056/NEJMoa0908806 · DOI
  4. Fagotti, 2020, Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850), Int. J. Gynecol. Cancer, 30, 1657, 10.1136/ijgc-2020-001640 · DOI
  5. Reuss, 2019, TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7), Int. J. Gynecol. Cancer, 29, 1327, 10.1136/ijgc-2019-000682 · DOI
  6. Katsumata, 2013, Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial, Lancet Oncol., 14, 1020, 10.1016/S1470-2045(13)70363-2 · DOI
  7. Clamp, 2019, Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial, Lancet, 394, 2084, 10.1016/S0140-6736(19)32259-7 · DOI
  8. Chan, 2016, Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer, N. Engl. J. Med., 374, 738, 10.1056/NEJMoa1505067 · DOI
  9. Trimble, 2006, Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma, Gynecol. Oncol., 100, 3, 10.1016/j.ygyno.2005.12.006 · DOI
  10. Armstrong, 2006, Intraperitoneal cisplatin and paclitaxel in ovarian cancer, N. Engl. J. Med., 354, 34, 10.1056/NEJMoa052985 · DOI
  11. Burger, 2011, Incorporation of bevacizumab in the primary treatment of ovarian cancer, N. Engl. J. Med., 365, 2473, 10.1056/NEJMoa1104390 · DOI
  12. Tewari, 2019, Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer, J. Clin. Oncol., 37, 2317, 10.1200/JCO.19.01009 · DOI
  13. Oza, 2015, ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial, Lancet Oncol., 16, 928, 10.1016/S1470-2045(15)00086-8 · DOI
  14. Moore, 2018, Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer, N. Engl. J. Med., 379, 2495, 10.1056/NEJMoa1810858 · DOI · Paper page
  15. Banerjee, 2021, Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol., 22, 1721, 10.1016/S1470-2045(21)00531-3 · DOI
  16. González-Martín, 2019, Niraparib in patients with newly diagnosed advanced ovarian cancer, N. Engl. J. Med., 381, 2391, 10.1056/NEJMoa1910962 · DOI
  17. Ray-Coquard, 2019, Olaparib plus bevacizumab as first-line maintenance in ovarian cancer, N. Engl. J. Med., 381, 2416, 10.1056/NEJMoa1911361 · DOI
  18. Varga, 2019, Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028, Gynecol. Oncol., 152, 243, 10.1016/j.ygyno.2018.11.017 · DOI
  19. Disis, 2019, Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial, JAMA Oncol., 5, 393, 10.1001/jamaoncol.2018.6258 · DOI
  20. Matulonis, 2019, Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study, Ann. Oncol., 30, 1080, 10.1093/annonc/mdz135 · DOI
  21. Moore, 2017, IMagyn050/GOG3015/ENGOT-ov39: a randomized, double-blind, phase III study of atezolizumab vs placebo combined with chemotherapy + bevacizumab in stage III-IV ovarian, fallopian tube & peritoneal cancers (OC), Ann. Oncol., 28, v330
  22. Berek, 2004, Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer, J. Clin. Oncol., 22, 3507, 10.1200/JCO.2004.09.016 · DOI
  23. Berek, 2009, Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer, J. Clin. Oncol., 27, 418, 10.1200/JCO.2008.17.8400 · DOI
  24. Lancaster, 2015, Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions, Gynecol. Oncol., 136, 3, 10.1016/j.ygyno.2014.09.009 · DOI
  25. Miller, 2020, ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer, Ann. Oncol., 31, 1606, 10.1016/j.annonc.2020.08.2102 · DOI
  26. Pujade-Lauraine, 2021, LBA33 maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): phase IIIb OReO/ENGOT Ov-38 trial. LBA33, Ann. Oncol., 32, S1283
  27. Morice, 2021, Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database, Lancet Haematol., 8, e122, 10.1016/S2352-3026(20)30360-4 · DOI
  28. van Driel, 2018, Hyperthermic intraperitoneal chemotherapy in ovarian cancer, N. Engl. J. Med., 378, 230, 10.1056/NEJMoa1708618 · DOI

Cited by

Sorted by citations

See all 26

Metadata

Authors
Hinchcliff, E., Westin, S. N., & Herzog, T. J.
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2022-07
Volume
166
Issue
1
Pages
18-24
ISSN
0090-8258
DOI
10.1016/j.ygyno.2022.04.021
Cited by
26
References
1
Language
en
Licence
Funders
National Institutes of Health (5P50 CA217685, P30 CA016672)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review